The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 61 | — | 20.1x | Near average | |
Growth | 48 | 75.9% | 5.6% | Near average | |
Quality | 70 | 162.2% | 7.6% | Above average | |
Safety | 33 | 0.2x | 0.4x | Below average | |
Capital Return | 92 | — | 2.19% | Above average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
BioCryst Pharmaceuticals, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy BioCryst Pharmaceuticals, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
BioCryst stock shows a state of stability in the average price target at 16.86 dollars, without any notable changes during the periods (day, week, month), indicating an absence of new catalysts that might prompt analysts to adjust their pricing models. However, we observe a significant dispersion in estimates, with targets ranging between a low of 8 dollars and a high of 25 dollars, reflecting a sharp division in the future outlook for the company.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.